These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 34208760)

  • 1. Current Approaches and Tools Used in Drug Development against Parkinson's Disease.
    Koszła O; Stępnicki P; Zięba A; Grudzińska A; Matosiuk D; Kaczor AA
    Biomolecules; 2021 Jun; 11(6):. PubMed ID: 34208760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapeutic strategy for Parkinson's and Alzheimer's disease.
    Esposito E; Cuzzocrea S
    Curr Med Chem; 2010; 17(25):2764-74. PubMed ID: 20586718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective strategies in Parkinson's disease : an update on progress.
    Mandel S; Grünblatt E; Riederer P; Gerlach M; Levites Y; Youdim MB
    CNS Drugs; 2003; 17(10):729-62. PubMed ID: 12873156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
    Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
    Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease.
    Liu B; Dluzen DE
    Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):555-65. PubMed ID: 17581209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of endoplasmic reticulum stress in Parkinson's disease.
    Tsujii S; Ishisaka M; Hara H
    Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
    Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
    CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective strategies in Parkinson's disease using the models of 6-hydroxydopamine and MPTP.
    Grünblatt E; Mandel S; Youdim MB
    Ann N Y Acad Sci; 2000; 899():262-73. PubMed ID: 10863545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta.
    Eriksen N; Stark AK; Pakkenberg B
    J Neural Transm Suppl; 2009; (73):203-13. PubMed ID: 20411779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.
    Simunovic F; Yi M; Wang Y; Macey L; Brown LT; Krichevsky AM; Andersen SL; Stephens RM; Benes FM; Sonntag KC
    Brain; 2009 Jul; 132(Pt 7):1795-809. PubMed ID: 19052140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Drug Repurposing for Parkinson's Disease.
    Chen X; Gumina G; Virga KG
    Curr Med Chem; 2019; 26(28):5340-5362. PubMed ID: 30027839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroprotective and neurorestorative therapies for the treatment of Parkinson's disease].
    Garbayo E; Aymerich MS; Ansorena E; Lanciego JL; Blanco-Prieto MJ
    An Sist Sanit Navar; 2006; 29(3):325-35. PubMed ID: 17224935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease.
    Pabon MM; Bachstetter AD; Hudson CE; Gemma C; Bickford PC
    J Neuroinflammation; 2011 Jan; 8():9. PubMed ID: 21266082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease.
    Galiano-Landeira J; Torra A; Vila M; Bové J
    Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroprotective Activities of Curcumin in Parkinson's Disease: A Review of the Literature.
    Nebrisi EE
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential role of cannabinoids in Parkinson's disease.
    Sevcík J; Masek K
    Drugs Aging; 2000 Jun; 16(6):391-5. PubMed ID: 10939305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.